ArticlePloS one2026
Design and evaluation of a novel expandable gastroretentive film for sustained Metoprolol release.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroretentive drug delivery systems (GRDDS) are designed to prolong gastric residence time and improve drug bioavailability. Among these, swelling-based expandable films offer the dual advantage of increased gastric retention and controlled drug release. Metoprolol tartrate, a β1-receptor blocker with a short half-life and low oral bioavailability, was selected as the model drug. This study aimed to develop and evaluate a novel swelling-based expandable gastroretentive film of Metoprolol using a 4 × 4 full factorial design to systematically investigate the effects of HPMC and Carbopol 934 concentrations. Sixteen formulations (F1-F16) were prepared by solvent casting and swelling index (SI) and in vitro drug release were chosen as response variables. The optimized film (F14) exhibited a high SI and sustained drug release, delivering ≈86% of Metoprolol over 12 hours. Kinetic modeling demonstrated first-order and Higuchi release patterns with a non-Fickian mechanism, while model-independent parameters (AIC, MSC, similarity factors) supported these findings. Characterization studies confirmed the robustness of F14: FTIR and XRD revealed no drug-polymer interaction and an amorphous drug state, while SEM showed a uniform surface with interconnected pores. Mechanical testing confirmed desirable tensile strength and flexibility. Radiographic evaluation in rabbits demonstrated that F14 expanded and remained in the stomach for up to 12 hours, validating its gastroretentive capacity. Furthermore, short-term stability testing under accelerated ICH conditions confirmed the film's physical and chemical stability and sustained-release performance for 6 weeks. In conclusion, the optimized expandable film (F14) combined swelling, gastric retention, and sustained drug release, highlighting its promise as a gastroretentive platform to enhance Metoprolol bioavailability and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.